장마감
로그인 회원가입
SGP
SGP
SpyGlass Pharma Inc
7월 27일 4:00 PM ET (한국 7/28 05:00)
$20.82
+0.33 ▲ +1.61%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$20.82
+0.00 +0.00%

스파이글래스팜(SGP) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$696M
스몰캡
P/E
-
배당수익률
없음
52주 위치
24%
저점 +22% · 고점 -36%
애널리스트
적극 매수
C+
Fundamental health
vs. 초고성장주 소형주· based on 2 axes
수익성
데이터 부족
성장
Top 69%
밸류에이션
데이터 부족
재무 안정
Top 25%
Index RUTP/E -EPS (ttm) -Insider Own 58.27%Shs Outstand 33.4MPerf Week 4%
Market Cap 0.70BForward P/E -EPS next Y -18.13%Insider Trans 245.47%Shs Float 13.9MPerf Month 10.69%
Enterprise Value 0.45BPEG -EPS next Q -0.51Inst Own 38.29%Short Float 8.11%Perf Quarter -11.48%
Income -P/S -EPS this Y 87.35%Inst Trans 25.29%Short Ratio 10.27Perf Half Y -
Sales -P/B 2.78EPS next 5Y 43.5%ROA -Short Interest 1.13MPerf YTD -13.25%
Book/sh 7.48P/C 2.77EPS past 3/5Y -69.04% -ROE -52W High -35.82% ($32.44)Perf Year -
Cash/sh 7.51P/FCF -Sales past 3/5Y -ROIC -52W Low 22.04% ($17.06)Perf 3Y -
Dividend Est. -EV/EBITDA -EPS Y/Y TTM -Gross Margin -Volatility(W/M) 7.23% 9.04%Perf 5Y -
Dividend TTM -EV/Sales -Sales Y/Y TTM -Oper. Margin -ATR (14) 1.53Perf 10Y -
Dividend Ex-Date -Quick Ratio 38EPS Q/Q -Profit Margin -RSI (14) 53.16Recom 1
Dividend Gr. 3/5Y -Current Ratio 38Sales Q/Q -SMA20 2% ($20.41)Beta -Target Price $45
Payout -Debt/Eq 0.01Earnings 2026/5/14SMA50 4.03% ($20.01)Rel Volume 0.51Prev Close $20.49
Employees 65LT Debt/Eq 0.01EPS/Sales Surpr. -37.15% -SMA200 -9.94% ($23.12)Avg Volume(3M) 0.11MPrice $20.82
IPO 2026/2/6Option/Short No/YesTrades 1451Volume 55,882Change 1.61%

📊 SpyGlass Pharma Inc (SGP) Investment Analysis

What kind of company is SpyGlass Pharma Inc?

스파이글래스팜(SGP) 초고성장주
Healthcare · Biotechnology
Healthcare Stocks

👁️ SpyGlass Pharma (SGP) is a U.S. biotech company developing long-acting drug delivery platforms targeting ophthalmic diseases. Its lead candidate incorporates bimatoprost into an intraocular lens implanted during cataract surgery, enabling long-term drug delivery for patients with glaucoma and elevated intraocular pressure. The company has achieved meaningful results in clinical-stage development and is pursuing a differentiated approach in the field of ophthalmic drug delivery.

Learn more about SpyGlass Pharma Inc →
Market Cap
$0.7B
Approx. KRW 1.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank2919
Employees65people
IPO2026/02/06
Current Price$20.82 ≈ 28,523원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 14일 (목) · 장 마감 후 EPS -37.1%
🔔 Earnings release 2026년 3월 26일 (목) · 장 마감 후 EPS -896.2%

Is it profitable?

Financial health solid
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.01
✓ Very low debt
My positionTop 25%
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
38.00
✓ 우수
My positionTop 5%
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
38.00
✓ 우수
My positionTop 5%
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$45.00
현재가 대비 +116.1%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
-18.1%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+43.5%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
2
예상 하회
0%
상회 비율
-493.9%
평균 서프라이즈
2026.05.14
하회
실적 $-0.69 · 예상 $-0.36 -91.7%
2026.03.26
하회
-896.2%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+87.3%
양호
My positionMid-range
Low range Average High range
초고성장주 소형주 Median 51.6% · Top 30%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
-18.1%
매우 부진
My positionBottom 5%
Low range Average High range
초고성장주 소형주 Median 33.7% · Bottom tier
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+43.5%
양호
My positionMid-range
Low range Average High range
초고성장주 소형주 Median 40.0% · Top 46%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
-69.0%
매우 부진
My positionBottom 5%
Low range Average High range
초고성장주 소형주 Median 6.9% · Bottom tier
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Returns by period
Current position within 52-week range
Low (-22.0%p) High (-35.8%p)
Current price is 22.0% above the 52-week low and 35.8% below the 52-week high
Recent risk (last 118 trading days)
Max drawdown
-40.8%
Annualized volatility
66.9%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 117-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢
Current diagnosis · 2026-07-27
Uptrend zone

Current price $20.82 above the midline ($20.41). Normal upward flow. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢
Current diagnosis · 2026-07-27
Bullish momentum holding

MACD 0.156 > Signal 0.092 in positive zone + Hist positive (+0.064). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 53.2 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 46.3.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Cheap
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
2.78x
✓ Cheap
My positionMid-range
Low range Average High range
Biotechnology 소형주 median 3.34x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
Analyst target price (reference)
$45.00 vs. current price +116.1%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership flow is positive
Insider net buying +245.5% · Institutional net buying +25.3% · Short interest moderate 8.1% · Short interest up +2.6pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
+245.5%
Insiders large net buying
🏦 Institutions (funds & investors)
+25.3%
Institutions large net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 38.3%
Moderate institutional participation
Healthcare 소형주 Median 65.6%
🧑‍💼 Insiders 58.3%
Founder/management large holders (strong skin-in-the-game)
Healthcare 소형주 Median 17.6%
👤 Retail investors (estimated) 3.4%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
8.1%
Moderate
Healthcare 소형주 Median 11.2%
Past 90 days 📈 +2.6%p increase
Short interest days to cover
10.3 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 33.4M주
Float (tradable shares) 13.9M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding SGP

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
SGP SGP This Stock
$696.1M- 2.8 - - +1.6%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 스파이글래스팜(SGP)?

스파이글래스팜(SGP) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of SGP?

The market cap of SGP is approximately $696M, ranking 2,919 within its sector.

What is the 52-week high and low for SGP?

SGP has recorded a 52-week high of $32.44 and a low of $17.06.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.